Clinical trial NCT03937596: Adjunctive D-Cycloserine in Major Depressive Disorder
Official title: A Randomized Placebo-controlled Trial of Adjunctive D-cycloserine in Repetitive Transcranial Magnetic Stimulation for Major Depressive Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Major Depressive Disorder
Lead sponsor: University of Calgary
Sponsor class: OTHER
First posted: 2019-05-06
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Transcranial magnetic stimulation (rTMS) is an approved treatment for depression. The purpose of this study is to test an adjunctive medication, D-cycloserine, in rTMS for depression using a placebo-controlled design. D-Cycloserine is a partial N-Methyl-D-Aspartate receptor (NMDAr) agonist, and therefore may enhance the effects of rTMS, however there is data to support and refute this hypothesis. Using a double-blind design, the investigators will randomize patients with Major Depressive Disorder to receive either daily low dose D-cycloserine or placebo in conjunction with rTMS to the left dorsolateral prefrontal cortex. After 10 treatments (2 weeks), this double-blind period will conclude and all participants will receive an additional 10 treatments (2 weeks) of rTMS without any adjuncts. The primary outcome will be improvement in clinician rated depressive symptoms at the conclusion of the study.

Detailed description: Major Depressive Disorder (MDD) is a common and debilitating illness. For an unacceptable proportion of patients, depressive symptoms remain impairing despite multiple treatments. Increasingly, non-invasive brain stimulation techniques are being explored as a means of targeting specific brain regions and networks that are implicated in depression. Repetitive transcranial magnetic stimulation (rTMS) is the non-invasive stimulation technique with the largest evidence base in MDD. Targeting the dorsolateral prefrontal cortex (DLPFC) with rTMS has proven an effective treatment for MDD, however as many as 2/3 of patients will not experience substantial improvement. Adjunctive agents are a potential strategy to improve patient outcomes.

The objective of the proposed study is to determine the efficacy of adjunctive D-cycloserine with rTMS directed to the left dorsolateral prefrontal cortex (DLPFC) in acute Major Depressive Episodes. The investigators propose to utilize a stimulation protocol called the intermittent theta-burst protocol to study rTMS in conjunction with D-cyloserine using a randomized double-blind, placebo-controlled design with allocation concealment. Patients with Major Depressive Disorder will be randomized to receive 1) rTMS+cycloserine, or 2) rTMS+placebo in a 1:1 ratio for two weeks (10 sessions).

At the conclusion of the 2-week blinded augmentation phase, patients will continue to receive two weeks of rTMS without an augmentation agent or placebo.

The primary outcome measures will be improvement in depression as measured by change in Montgomery Asberg Depression Rating Scale (MADRS). In addition, the investigators will also be looking at the improvement of other clinical outcome measures, quality of life and changes in brain functional dynamics, as assessed with functional Magnetic Resonance Imaging (MRI), and metabolites, as assessed by Magnetic Resonance (MR) Spectroscopy.

Eligibility criteria: Inclusion Criteria:

* are competent to consent to treatment
* have a Mini-International Neuropsychiatric Interview (MINI) confirmed diagnosis of DSM-5 criteria Major Depressive Disorder with a current episode of at least moderate severity of depression, single or recurrent
* have failed to achieve a clinical response to one adequate trial of antidepressant medication within the current episode, or been unable to tolerate antidepressant medications.
* have a score ≥ 18 on the Hamilton Depression Rating Scale 17-item
* have a Young Mania Rating Scale Score of ≤ 8
* have had no change in dose, or initiation of any psychotropic medication in the 4 weeks prior to randomization
* are able to adhere to the treatment schedule
* pass the TMS adult safety screening (TASS) questionnaire

Exclusion Criteria:

* Allergy to Cycloserine
* Have failed adequate trials of ≥4 antidepressant treatments in the current episode.
* have an alcohol or substance use disorder within the last 3 months
* have suicidal ideation (score of 4 ≥ on item 10 of MADRS)
* are at a significant risk of harm to themselves or others
* history of psychosis
* are currently pregnant , breast feeding or plan to become pregnant
* have a lifetime Mini-International Neuropsychiatric Interview (MINI) diagnosis of other primary psychiatric diagnoses as assessed by a study investigator to be primary and causing greater impairment than Major Depressive Disorder.
* have failed a course of electroconvulsive therapy (ECT) in the current episode. Previous ECT treatment outside of the current episode does not influence inclusion.
* history of non-response to rTMS treatment.
* have any significant neurological disorder or insult including, but not limited to: any condition likely to be associated with increased intracranial pressure, space occupying brain lesion, any history of epilepsy, cerebral aneurysm, Parkinson's disease, Huntington's chorea, multiple sclerosis, significant head trauma with loss of consciousness for greater than or equal to 5 minutes
* have concomitant major unstable medical illness, cardiac pacemaker or implanted medication pump
* have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metal object within or near the head, excluding the mouth, that cannot be safely removed
* If participating in psychotherapy, must have been in stable treatment for at least 3 months prior to entry into the study, with no anticipation of change in the frequency of therapeutic sessions, or the therapeutic focus over the duration of the study
* are currently (or in the last 4 weeks) taking lorazepam or any other benzodiazepine due to the potential to limit rTMS efficacy
* have an exclusion criteria for MRI: Those with a history of cranial, thoracic or abdominal surgery, with pacemakers, artificial joints or other metallic implants will be excluded from the MRI scan. Subjects that have agreed to participate in the MRI portion of the study will be pre-screened for any potential metal fragments in the body (particularly in the orbits) if they have had any history of doing metal work or have been involved in use/deployment of ammunitions/explosives, welding, piping etc).

Primary outcomes:
measure: Montgomery-Asberg Depression Rating Scale (MADRS)
timeFrame: Administered at baseline, at the halfway point (week 2), and after rTMS treatment (week 4)
Secondary outcomes:
measure: Functional Magnetic Resonance Imaging (fMRI)
timeFrame: Administered at baseline and week 2. Change in cycloserine group vs change in placebo group
measure: Magnetic Resonance (MR) spectroscopy
timeFrame: Administered at baseline and week 2. Change in cycloserine group vs change in placebo group
measure: Clinical Remission
timeFrame: Administered at baseline, at the halfway point (week 2), and after rTMS treatment (week 4)
measure: Clinical Response
timeFrame: Administered at baseline, at the halfway point (week 2), and after rTMS treatment (week 4)
measure: Quality of Life as measured by the World Health Organization Quality of Life (WHOQOL-BREF) questionnaire
timeFrame: Administered at baseline, week 1, at the halfway point (week 2), week 3, and after rTMS treatment (week 4)
measure: Anxiety Symptoms
timeFrame: Administered at baseline, week 1, at the halfway point (week 2), week 3, and after rTMS treatment (week 4)
measure: Workplace Productivity
timeFrame: Administered at baseline, week 1, at the halfway point (week 2), week 3, and after rTMS treatment (week 4)
measure: Functional Disability
timeFrame: Administered at baseline, week 1, at the halfway point (week 2), week 3, and after rTMS treatment (week 4)
measure: Clinical Global Impression
timeFrame: Administered at baseline, at the halfway point (week 2), and after rTMS treatment (week 4)
measure: Cognitive Function
timeFrame: Administered at baseline and at the halfway point (week 2)
measure: Implicit Suicidal Thoughts
timeFrame: Administered at baseline and at the halfway point (week 2)
measure: Personality Measures- BFI
timeFrame: Administered at baseline and after rTMS treatment (week 4)
measure: Personality Measures- DEQ
timeFrame: Administered at baseline and after rTMS treatment (week 4)
measure: Anhedonia
timeFrame: Administered at baseline and after rTMS treatment (week 4)
measure: Self-reported Cognition
timeFrame: Administered at baseline, week 1, at the halfway point (week 2), week 3, and after rTMS treatment (week 4)
measure: Depressive Symptoms
timeFrame: Administered at baseline, week 1, at the halfway point (week 2), week 3, and after rTMS treatment (week 4)
measure: VAS for General Health
timeFrame: Administered at baseline, at the halfway point (week 2), and after rTMS treatment (week 4)
measure: Perception of Illness
timeFrame: Administered at baseline and after rTMS treatment (week 4)
Other outcomes:
measure: Incidence of Treatment-Emergent Adverse Events
timeFrame: Daily Monday-Friday throughout study (4 weeks)
measure: Side Effects
timeFrame: Daily Monday-Friday throughout study (4 weeks)
Locations:
city: Calgary
country: Canada
facility: University of Calgary
state: Alberta
Study officials:
affiliation: University of Calgary
name: Alexander McGirr, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Cole J, Sohn MN, Harris AD, Bray SL, Patten SB, McGirr A. Efficacy of Adjunctive D-Cycloserine to Intermittent Theta-Burst Stimulation for Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022 Dec 1;79(12):1153-1161. doi: 10.1001/jamapsychiatry.2022.3255.